Valeant Pharmaceuticals International
Tel: 800-548-5100 or 949-461-6000
About Valeant Pharmaceuticals InternationalValeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
CEO: Joseph C. Papa
CMO: Tage Ramakrishna
CFO: Robert Rosiello
Please click here for clinical trial information.
Please click here for Valeant job opportunities.
953 articles with Valeant Pharmaceuticals International
In aggregate, Valeant has now reduced its debt by more than $6.5B since the end of the first quarter of 2016.
Kessler Topaz Represents Investors in $290M Total Settlement Recovery Reached with Valeant Pharmaceuticals and Bill Ackman’s Pershing Square Over Insider Trading Claims
In settling the claims, Valeant and Pershing Square agreed to jointly pay a total of $290M for all involved investors.
From around 2014 through 2016, Valeant seemingly had a crisis story per week, ranging from insider trading to channel stuffing
Valeant today announced that its affiliate has completed the divestiture of the Sprout to Sprout2, an entity affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of ADDYI beginning in May 2019.
Billionaire George Soros Bets Big Against 2 Struggling Drugmakers , But One Could Make a Big Come...
12/19/2017Should you invest the way billionaire investors do?
Valeant and One of Its Subsidiaries Announce Early Tender Results and Early Settlement Date on December 18 for Cash Tender Offers for Senior Notes
Valeant announced today the results to date of the pending cash tender offers by Valeant and Valeant Pharmaceuticals International to purchase up to $1,500,000,000 aggregate principal amount
Bausch + Lomb Begins Distribution of VYZULTA (Latanoprostene Bunod Ophthalmic Solution), 0.024% to U.S. Wholesalers
Valeant today announced that it has begun distributing VYZULTA.
The Notes will be guaranteed by each of the Company's subsidiaries that are guarantors under the Company's credit agreement and the Company's existing senior notes.
The Company also announced today that it has provided notice to its lenders of its intent to repay $175M of amounts outstanding under its revolving credit facility this week, using cash on hand.
Valeant Pharma and One of its Subsidiaries Commence Cash Tender Offers for Up to $1,000,000,000 Outstanding Principal Amount
Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.
11/30/2017As 2017 comes to a close, 40 drugs have been approved so far, with the record being in 2015, when 46 drugs were approved.
Valeant used the net proceeds from the offering of the Notes, along with cash on hand, to prepay a portion of its outstanding Series F Tranche B Term Loans due 2022 and to pay related fees and expenses.
Bausch & Lomb Helps to Recycle More Than One Million Units of Contact Lens Materials Within First Year of Launching the ONE by ONE Recycling Program
Valeant wholly owned subsidiary, Bausch & Lomb, today announced that its unique ONE by ONE Recycling Program has recycled a combined total of more than one million used contact lenses, blister packs and top foils in less than one year since its launch.
Valeant announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025.
Today, the U.S. Patent & Trademark Office granted Argentum Pharma's petition for IPR against all patent claims in the first patent listed in the FDA's Orange Book as covering Valeant's JUBLIA. Argentum is challenging all claims of U.S. Patent No. 7,214,506.
Valeant announced today that it has launched an offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025.
Valeant is not the only company to recently push reporters to defy the SEC’s orders.
Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
Valeant will use approximately $180M of the net proceeds from the sale to repay term loan debt under its Senior Credit Facility.
Increased revenue in the Bausch + Lomb/International segment by 1% compared to the third quarter of 2016.
A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi.